金沙博彩

金沙博彩

Service Platform

产品系列


Indication

Product

Dosage Form

Strength&

Package form

Intended

Market

Status

Anti-epilepsy

Carbamazepine

Sustained

Release Tablets

100mg,200mg&400mg

100CT/Bottle

US/China

FDA: Approved

NMPA: Approved

Oxcarbazepine

Tablets

150mg,300mg

Blister

China

150 mg:Under review

300 mg:Approved

Oxcarbazepine

Oral suspension

100ml:6g

China

Under Review

Lacosamide

Tablets

50mg,100mg

Blister

China

Approved

Antidiabetic

Sitagliptin +

Metformin

Sustained

Release Tablets

US market:

100/1000,50/1000

China: 100/1000,50/1000,50/500

US/China

FDA: Under review

NMPA:Under review

Sitagliptin

Phosphate

Tablets

50mg,100mg

Blister

China

Approved

Sitagliptin +

Metformin

Tablets

50mg/850mg

Blister

China

Approved

Gliclazide

Sustained

Release Tablets

60mg

Blister

China

Approved

Dapagliflozin +

Metformin

Sustained

Release Tablets

5mg/500mg

5mg/1000mg

10mg/500mg

10mg/1000mg

Blister

China

To be submitted in Nov.2025

Antidepressant

Venlafaxine

Hydrochloride

Sustained

Release Capsules

75mg

Blister

China

Approved

Vortioxetine

Hydrobromide

Tablets

5mg,10mg

Blister

China

Under Review

Anticoagulant

Edoxaban Tosylate

Tablets

30mg,60mg

Blister

China

Under Review

ED

Sildenafil Citrate

Orally

Disintegrating Tablets

50mg

Blister

China

Approved

PD

Rasagiline

Mesylate

Tablets

1mg

Blister

China

Under Review

Potassium-competitive acid blocker

Vonoprazan

Fumarate

Tablets

10mg,20mg

Blister

China

Under Review

Antianxiety

Tandospirone

Citrate

Tablets

5mg,10mg

Blister

China

Under Review

Anti-influenza

Baloxavir Marboxil

Tablets

20mg, 40mg

Blister

China

Under Review

NSAIDs

Diclofenac Diethylamine

Gel

Topical

1%: 20g/tube,50g/tube

2.32%: 50g/tube

China

1%:To be submitted in Mar.2026;

2.32%:To be submitted in Nov.2025

NSAIDs

Ketoprofen

Gel

Topical

2.5%:20g/tube,50g/tube

China

To be submitted in Nov.2025

商务合作

创新药CDMO服务

成熟业务服务(API)

人力资源部

招贤纳士

金沙博彩

官方微信公众号

Sorry,当前栏目暂无内容!

您可以查看其他栏目或返回 首页

Sorry,The current column has no content!

You can view other columns or return Home

太阳城集团 im电竞官网平台 澳门威尼斯人网上赌场 皇冠直营 亚洲体育博彩平台